|
1
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jain RK: Anti-angiogenesis strategies
revisited: From starving tumors to alleviating hypoxia. Cancer
Cell. 26:605–622. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jain RK: Normalization of tumor
vasculature: an emerging concept in antiangiogenic therapy.
Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jain RK: Normalizing tumor vasculature
with anti-angiogenic therapy: A new paradigm for combination
therapy. Nat Med. 7:987–989. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cobleigh MA, Langmuir VK, Sledge GW,
Miller KD, Haney L, Novotny WF, Reimann JD and Vassel A: A phase
I/II dose-escalation trial of bevacizumab in previously treated
metastatic breast cancer. Semin Oncol. 30 5 Suppl 16:S117–S124.
2003. View Article : Google Scholar
|
|
6
|
Goel S, Duda DG, Xu L, Munn LL, Boucher Y,
Fukumura D and Jain RK: Normalization of the vasculature for
treatment of cancer and other diseases. Physiol Rev. 91:1071–1121.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carmeliet P and Jain RK: Molecular
mechanisms and clinical applications of angiogenesis. Nature.
473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hernández-Agudo E, Mondejar T,
Soto-Montenegro ML, Megías D, Mouron S, Sanchez J, Hidalgo M,
Lopez-Casas PP, Mulero F, Desco M, et al: Monitoring vascular
normalization induced by antiangiogenic treatment with
18F-fluoromisonidazole-PET. Mol Oncol. 10:704–718. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bao X, Wang MW, Luo JM, Wang SY, Zhang YP
and Zhang YJ: Optimization of early response monitoring and
prediction of cancer anti-angiogenesis therapy via noninvasive PET
molecular imaging strategies of multifactorial bioparameters.
Theranostics. 6:2084–2098. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Park SW, Zhen GH, Verhaeghe C, Nakagami Y,
Nguyenvu LT, Barczak AJ, Killeen N and Erle DJ: The protein
disulfide isomerase AGR2 is essential for production of intestinal
mucus. Proc Natl Acad Sci USA. 106:6950–6955. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu D, Rudland PS, Sibson DR,
Platt-Higgins A and Barraclough R: Human homologue of cement gland
protein, a novel metastasis inducer associated with breast
carcinomas. Cancer Res. 65:3796–3805. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fritzsche FR, Dah E, Pahl S, Burkhardt M,
Luo J, Mayordomo E, Gansukh T, Dankof A, Knuechel R, Denkert C, et
al: Prognostic relevance of AGR2 expression in breast cancer. Clin
Cancer Res. 12:1728–1734. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Innes HE, Liu D, Barraclough R, Davies MP,
O'Neill PA, Platt-Higgins A, de Silva Rudland S, Sibson DR and
Rudland PS: Significance of the metastasis-inducing protein AGR2
for outcome in hormonally treated breast cancer patients. Br J
Cancer. 94:1057–1065. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang Z, Hao Y and Lowe AW: The
adenocarcinoma-associated antigen, AGR2, promotes tumor growth,
cell migration, and cellular transformation. Cancer Res.
68:492–497. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ramachandran V, Arumugam T, Wang HM and
Logsdon CD: Anterior gradient 2 is expressed and secreted during
the development of pancreatic cancer and promotes cancer cell
survival. Cancer Res. 68:7811–7818. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang YX, Ali TZ, Zhou H, D'Souza DR, Lu
Y, Jaffe J, Liu Z, Passaniti A and Hamburger AW: ErbB3 binding
protein 1 represses metastasis-promoting gene anterior gradient
protein 2 in prostate cancer. Cancer Res. 70:240–248. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gao H, Xu XC, Chen B, Wang F, Zhang W,
Geng H and Wang Y: Anterior gradient 2: A new target to treat
colorectal cancer. Med Hypotheses. 80:706–708. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hong XY, Wang J and Li Z: AGR2 expression
is regulated by HIF-1 and contributes to growth and angiogenesis of
glioblastoma. Cell Biochem Biophys. 67:1487–1495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chevet E, Fessart D, Delom F, Mulot A,
Vojtesek B, Hrstka R, Murray E, Gray T and Hupp T: Emerging roles
for the pro-oncogenic anterior gradient-2 in cancer development.
Oncogene. 32:2499–2509. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brychtova V, Vojtesek B and Hrstka R:
Anterior gradient 2: A novel player in tumor cell biology. Cancer
Lett. 304:1–7. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Valladares-Ayerbes M, Blanco-Calvo M,
Reboredo M, Lorenzo-Patiño MJ, Iglesias-Díaz P, Haz M, Díaz-Prado
S, Medina V, Santamarina I, Pértega S, et al: Evaluation of the
adenocarcinoma-associated gene AGR2 and the intestinal stem cell
marker LGR5 as biomarkers in colorectal cancer. Int J Mol Sci.
13:4367–4387. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xue H, Lü B, Zhang J, Wu M, Huang Q, Wu Q,
Sheng H, Wu D, Hu J and Lai M: Identification of serum biomarkers
for colorectal cancer metastasis using a differential secretome
approach. J Proteome Res. 9:545–555. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Z, Zhu Q, Hu L, Chen H, Wu Z and Li D:
Anterior gradient 2 is a binding stabilizer of hypoxia inducible
factor-1α that enhances CoCl2-induced doxorubicin resistance in
breast cancer cells. Cancer Sci. 106:1041–1049. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pan Y, Wu Q, Liu R, Shao M, Pi J, Zhao X
and Qin L: Inhibition effects of gold nanoparticles on
proliferation and migration in hepatic carcinoma-conditioned
HUVECs. Bioorg Med Chem Lett. 24:679–684. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pan Y, Wu Q, Qin L, Cai J and Du B: Gold
nanoparticles inhibit VEGF165-induced migration and tube formation
of endothelial cells via the Akt pathway. Biomed Res Int.
2014:4186242014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pan Y, Ding H, Qin L, Zhao X, Cai J and Du
B: Gold nanoparticles induce nanostructural reorganization of
VEGFR2 to repress angiogenesis. J Biomed Nanotechnol. 9:1746–1756.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ernsting MJ, Murakami M, Roy A and Li SD:
Factors controlling the pharmacokinetics, biodistribution and
intratumoral penetration of nanoparticles. J Control Release.
172:782–794. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li Y, Lian Y, Zhang LT, Aldousari SM,
Hedia HS, Asiri SA and Liu WK: Cell and nanoparticle transport in
tumour microvasculature: The role of size, shape and surface
functionality of nanoparticles. Interface Focus. 6:201500862016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Baban DF and Seymour LW: Control of tumour
vascular permeability. Adv Drug Deliv Rev. 34:109–119. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li W, Zhao X, Du B, Li X, Liu S, Yang XY,
Ding H, Yang W, Pan F, Wu X, et al: gold nanoparticle-mediated
targeted delivery of recombinant human endostatin normalizes tumour
vasculature and improves cancer therapy. Sci Rep. 6:306192016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Franco M, Man S, Chen L, Emmenegger U,
Shaked Y, Cheung AM, Brown AS, Hicklin DJ, Foster FS and Kerbel RS:
Targeted anti-vascular endothelial growth factor receptor-2 therapy
leads to short-term and long-term impairment of vascular function
and increase in tumor hypoxia. Cancer Res. 66:3639–3648. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yonenaga Y, Mori A, Onodera H, Yasuda S,
Oe H, Fujimoto A, Tachibana T and Imamura M: Absence of smooth
muscle actin-positive pericyte coverage of tumor vessels correlates
with hematogenous metastasis and prognosis of colorectal cancer
patients. Oncology. 69:159–166. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gille H, Kowalski J, Li B, LeCouter J,
Moffat B, Zioncheck TF, Pelletier N and Ferrara N: Analysis of
biological effects and signaling properties of Flt-1 (VEGFR-1) and
KDR (VEGFR-2). A reassessment using novel receptor-specific
vascular endothelial growth factor mutants. J Biol Chem.
276:3222–3230. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Facciabene A, Peng X, Hagemann IS, Balint
K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L and
Coukos G: Tumour hypoxia promotes tolerance and angiogenesis via
CCL28 and Treg cells. Nature. 475:226–230. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kani K, Malihi PD, Jiang Y, Wang H, Wang
Y, Ruderman DL, Agus DB, Mallick P and Gross ME: Anterior gradient
2 (AGR2): Blood-based biomarker elevated in metastatic prostate
cancer associated with the neuroendocrine phenotype. Prostate.
73:306–315. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen R, Pan S, Duan X, Nelson BH, Sahota
RA, de Rham S, Kozarek RA, McIntosh M and Brentnall TA: Elevated
level of anterior gradient-2 in pancreatic juice from patients with
pre-malignant pancreatic neoplasia. Mol Cancer. 9:1492010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chung K, Nishiyama N, Yamano S, Komatsu H,
Hanada S, Wei M, Wanibuchi H, Suehiro S and Kakehashi A: Serum AGR2
as an early diagnostic and postoperative prognostic biomarker of
human lung adenocarcinoma. Cancer Biomark. 10:101–107. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tohti M, Li J, Tang C, Wen G, Abdujilil A,
Yizim P and Ma C: Serum AGR2 as a useful biomarker for pituitary
adenomas. Clin Neurol Neurosurg. 154:19–22. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Di Maro G, Salerno P, Unger K, Orlandella
FM, Monaco M, Chiappetta G, Thomas G, Oczko-Wojciechowska M,
Masullo M, Jarzab B, et al: Anterior gradient protein 2 promotes
survival, migration and invasion of papillary thyroid carcinoma
cells. Mol Cancer. 13:1602014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mostert B, Sieuwerts AM, Bolt-de Vries J,
Kraan J, Lalmahomed Z, van Galen A, van der Spoel P, de Weerd V,
Ramírez-Moreno R, Smid M, et al: mRNA expression profiles in
circulating tumor cells of metastatic colorectal cancer patients.
Mol Oncol. 9:920–932. 2015. View Article : Google Scholar : PubMed/NCBI
|
